Cargando…
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival
Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk,...
Autores principales: | Ramos, Jorge D., Casey, Martin F., Crabb, Simon J., Bamias, Aristotelis, Harshman, Lauren C., Wong, Yu‐Ning, Bellmunt, Joaquim, De Giorgi, Ugo, Ladoire, Sylvain, Powles, Thomas, Pal, Sumanta K., Niegisch, Guenter, Recine, Federica, Alva, Ajjai, Agarwal, Neeraj, Necchi, Andrea, Vaishampayan, Ulka N., Rosenberg, Jonathan E., Galsky, Matthew D., Yu, Evan Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269690/ https://www.ncbi.nlm.nih.gov/pubmed/28000388 http://dx.doi.org/10.1002/cam4.986 |
Ejemplares similares
-
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
por: Del Bene, Gabriella, et al.
Publicado: (2018) -
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022) -
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016) -
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
por: van der Heijden, Michiel S., et al.
Publicado: (2022) -
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
por: Grivas, Petros, et al.
Publicado: (2018)